Aripiprazole metabolic pathway (WP2640)

Homo sapiens

Open in new tab Open in NDEx
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
The CYP P450 metabolism of aripiprazole has been studied and described in several papers (like the one in the bibliography), except for the original primary literature describing the experiments and the exact metabolite structures. The two CYPs are said to be involved in N-dealkylation and dehydrogenation.

Authors

Egon Willighagen and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Pathway Ontology

xenobiotic metabolic pathway phase I biotransformation pathway via cytochrome P450

Participants
Query Drugst.One

Label Type Compact URI Comment
aripiprazole Metabolite hmdb:HMDB0005042
dehydroaripiprazole Metabolite pubchem.compound:10114519 Also known as OPC14857.
Product Metabolite chebi:25212
CYP2D6 GeneProduct ensembl:ENSG00000100197
CYP3A43 GeneProduct ensembl:ENSG00000021461

References

  1. Aripiprazole, a novel atypical antipsychotic drug. Argo TR, Carnahan RM, Perry PJ. Pharmacotherapy. 2004 Feb;24(2):212–28. PubMed Europe PMC Scholia
  2. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T, Perry CM. Drugs. 2004;64(15):1715–36. PubMed Europe PMC Scholia
  3. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, et al. Drug Metab Pharmacokinet. 2005 Feb;20(1):55–64. PubMed Europe PMC Scholia
  4. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Molden E, Lunde H, Lunder N, Refsum H. Ther Drug Monit. 2006 Dec;28(6):744–9. PubMed Europe PMC Scholia
  5. Metabolic drug interactions with newer antipsychotics: a comparative review. Spina E, de Leon J. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4–22. PubMed Europe PMC Scholia